Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Delcath Systems, Inc. of Class Action Lawsuit and

Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in
Delcath Systems, Inc. of Class Action Lawsuit and Upcoming Deadline -- DCTH

NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- Pomerantz Grossman Hufford
Dahlstrom & Gross LLP has filed a class action lawsuit against Delcath
Systems, Inc. ("Delcath" or the "Company") (Nasdaq:DCTH) and certain of its
officers. The class action, filed in United States District Court, Southern
District of New York, and docketed under 13 CIV 3116, is on behalf of a class
consisting of all persons or entities who purchased or otherwise acquired
securities of Delcath between April 21, 2010 and May 2, 2013, both dates
inclusive (the "Class Period"). This class action seeks to recover damages
against the Company and certain of its officers and directors as a result of
alleged violations of the federal securities laws pursuant to Sections 10(b)
and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated
thereunder.

If you are a shareholder who purchased Delcath securities during the Class
Period, you have until July 8, 2013 to ask the Court to appoint you as Lead
Plaintiff for the class. A copy of the Complaint can be obtained at
www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby
at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237.
Those who inquire by e-mail are encouraged to include their mailing address,
telephone number, and number of shares purchased.

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical
device company focusing on the field of oncology. The company's proprietary
technology enables the administration of high-dose chemotherapy and other
therapeutic agents to diseased organs or regions of the body, while
controlling the systemic exposure of those agents.

The Complaint alleges that throughout the Class Period, Defendants made false
and/or misleading statements, as well as failed to disclose material adverse
facts about the Company's business, operations, and prospects.Specifically,
Defendants made false and/or misleading statements and/or failed to disclose
that: (1) the Company's New Drug Application ("NDA") for Melblez Kit (Melblez
(melphalan) for Injection for use with the (Delcath Hepatic Delivery System),
for the treatment of patients with unresectable ocular melanoma metastatic to
the liver contained risks including substantial and severe toxicity and deaths
associated with the drug's adverse reactions; and (2) the Company's
manufacturing facilities were in violation of Current Good Manufacturing
Practices ("cGMP").

On February 22, 2011, the Company disclosed that it had received a "refusal to
file" letter from the U.S. Food & Drug Administration ("FDA") for its NDA for
its proprietary chemosaturation system.The letter "requested information
involving manufacturing plant inspection timing, product and sterilization
validations and additional safety information […] as well as additional
statistical analysis clarification."On this news, Delcath shares plummeted
$4.29 or 38%, to close at $7.01 per share.

On April 30, 2013, the FDA published briefing documents ahead of a May 2, 2013
meeting by the Oncologic Drugs Advisory Committee ("ODAC").The briefing
documents concluded, among other things, that "substantial evidence of
effectiveness in adequate and well controlled clinical trials utilizing the
proposed drug-device combination product and a favorable benefit risk profile
is required for approval."Moreover, the briefing documents revealed that a
staggering 7% of the 122 patients treated with the Melbaz kit died as a result
of the treatment.On this news, Delcath shares declined $0.558 per share or
over 40%, to close at $0.832 per share on April 30, 2013.

On May 2, 2013, the Company announced that the ODAC voted 16 to 0 that
benefits of treatment with Delcath's Melblez Kit do not outweigh the risks
associated with the procedure.On this news, Delcath shares declined $0.3326
per share or nearly 42%, to close at $0.46 per share on May 3, 2013.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego,
is acknowledged as one of the premier firms in the areas of corporate,
securities, and antitrust class litigation. Founded by the late Abraham L.
Pomerantz, known as the dean of the class action bar, the Pomerantz Firm
pioneered the field of securities class actions. Today, more than 70 years
later, the Pomerantz Firm continues in the tradition he established, fighting
for the rights of the victims of securities fraud, breaches of fiduciary duty,
and corporate misconduct. The Firm has recovered numerous multimillion-dollar
damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT: Robert S. Willoughby
         Pomerantz Grossman Hufford Dahlstrom & Gross LLP
         rswilloughby@pomlaw.com